Ruxolitinib is an oral Janus kinase (JAK) inhibitor used to treat certain cancers and inflammatory conditions. A topical cream formulation containing 1.5% ruxolitinib API produced using high-purity ruxolitinib API from a reputable manufacturer has shown promise for treating atopic dermatitis (AD). Mechanism of Action As a JAK1 and JAK2 inhibitor, topical ruxolitinib works locally to suppress...